Brainomix Raises £14M to Propel AI Imaging in Healthcare
Deal News | Mar 20, 2025 | PR Newswire Cision Brainomix
Brainomix, an AI-focused healthcare technology company originating from the University of Oxford, has successfully completed a £14M ($18M) Series C funding round to enhance the deployment of its innovative imaging solutions, particularly in the domains of stroke and lung fibrosis. The funding, co-led by Parkwalk Advisors, Boehringer Ingelheim Venture Fund, and the Hostplus Innovation Fund managed by IP Group, underscores Brainomix’s mission to expand its commercial operations in the US and increase clinical adoption of its AI software globally. Its Brainomix 360 Stroke platform, endorsed by NICE, has significantly elevated treatment rates and improved patient outcomes in over 300 hospitals worldwide. With ten FDA clearances in the US, the company plans to advance the adoption of its e-Lung technology for lung fibrosis and bolster its presence across 20 countries. This additional investment is set to propel the company further into the market, enhancing accessibility to life-saving AI-driven diagnostics and treatments.
Sectors
- Healthcare Technology
- Artificial Intelligence
- Venture Capital
Geography
- United Kingdom – Brainomix is a University of Oxford spinout with operations in the UK.
- United States – The article highlights Brainomix’s plans to accelerate its commercial expansion into the US market.
- Australia – One of the new investors, Hostplus, is an Australian industry superannuation fund.
Industry
- Healthcare Technology – The article discusses advancements in AI-powered imaging tools designed for healthcare purposes, specifically targeting stroke and lung fibrosis.
- Artificial Intelligence – Brainomix develops AI-driven platforms that improve diagnostic and treatment processes in medical settings.
- Venture Capital – The Series C funding round involves multiple investors in the venture capital field, including Parkwalk Advisors and Boehringer Ingelheim Venture Fund.
Financials
- £14M ($18M) – The total amount raised in the Series C funding round completed by Brainomix.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Brainomix | Target Company | Company | A University of Oxford spinout pioneering AI-powered imaging solutions in stroke and lung fibrosis. |
| Parkwalk Advisors | Investor | Company | UK's largest growth EIS fund manager and a lead investor in the Series C round. |
| Boehringer Ingelheim Venture Fund | Investor | Company | A venture fund dedicated to investing in groundbreaking biotechnology companies. |
| Hostplus | Investor | Company | An Australian industry superannuation fund participating via the IP Group Hostplus Innovation Fund. |
| IP Group | Investment Manager | Company | Manages the Hostplus Innovation Fund and invests in deep-tech companies. |
| University of Oxford | Origin | Organization | The academic institution from which Brainomix originated as a spinout. |
| LifeSci Capital | Support | Company | Provided support for the Series C funding round. |